A Phase 1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX 2-73 in Healthy Male Subjects

Trial Profile

A Phase 1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX 2-73 in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2017

At a glance

  • Drugs ANAVEX 2-73 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Anavex Life Sciences
  • Most Recent Events

    • 04 Nov 2017 According to an Anavex Life Sciences media release, data from this trial were presented at the 2017 Clinical Trials on Alzheimer's Disease (CTAD) Meeting.
    • 17 Nov 2014 Full results were presented at CNS Summit 2014, according to an Anavex Life Sciences media release.
    • 17 Nov 2014 Results published in Anavex Life Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top